Sana Biotechnology, Inc. (NASDAQ: SANA)

Sana Biotechnology, Inc. is a biotechnology company focused on developing engineered cell therapies to treat serious diseases. The company uses two technology platforms to create cells that can avoid immune system detection and to deliver genetic material inside the body. Its lead programs are a stem cell derived islet cell therapy for type 1 diabetes and an inside the body chimeric antigen receptor T cell approach for B cell malignancies and autoimmune conditions.

Sana Biotechnology, Inc. does not currently sell any approved products and therefore does not generate revenue from product sales. The company funds its research and development activities through public and private equity offerings, collaborations and grant funding.

The company operates through the following segments: Outside the Body Cell Engineering and Inside the Body Cell Engineering.

• Outside the Body Cell Engineering uses the company's hypoimmune technology to produce allogeneic cells that evade detection by the recipient's immune system, with a focus on stem cell derived islet cells for type 1 diabetes, including the product candidate SC451 that is intended for transplantation without immunosuppression.

• Inside the Body Cell Engineering employs the fusogen platform to deliver genetic material to specific cell types inside the body, aiming to generate chimeric antigen receptor T cells that can target B cells in malignancies and autoimmune diseases, with the product candidate SG293 designed to create therapeutic cells directly in patients.

Sana Biotechnology, Inc. occupies an early stage position in the cell therapy field. It competes with larger companies that have approved cell therapies such as Vertex Pharmaceuticals, CRISPR Therapeutics and Allogene Therapeutics. Its differentiation lies in the hypoimmune approach that prevents both alloimmune and autoimmune rejection and the fusogen platform that enables in vivo generation of CAR T cells.

Sana Biotechnology, Inc. does not yet have commercial customers. Its programs are tested in clinical studies involving patients with type 1 diabetes and B cell related diseases. The company works with academic medical centers and research organizations to conduct trials and gather data.